Indian bio-pharmaceuticals developer Strides Shasun has signed an agreement with Apotex to merge with the latter’s Australian subsidiary, Apotex.

A new entity controlled by Strides will be formed following the transaction. The businesses of Strides and Apotex will run independently under the Arrow and Apotex brands respectively.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The merger will help Strides to increase its revenue in the Australian generic pharmaceutical market.

Japanese pharmaceutical company Takeda Pharmaceutical has agreed to acquire Shire, a biopharmaceutical company based in Ireland, for £46bn ($62.26bn).

The acquisition was finalised after revising Takeda’s fourth proposal of £44.3bn ($59.96bn). Three previous proposal offers were made by Takeda for the acquisition of Shire for £41bn ($55.49bn), £43bn ($58.2bn) and £44bn ($59.55bn).

Shire will become a subsidiary of Takeda and will own approximately half of the combined group, as per the acquisition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“US-based pharmaceutical company Eli Lilly and Company (Lilly) has agreed to acquire ARMO Biosciences for $1.6bn.”

The acquisition will help Takeda in delivering rare disease and plasma-derived therapies and also boost oncology drugs and vaccine development.

The headquarters of the combined company will be located in Japan, upon completion of the acquisition in the first half of 2019.

US-based pharmaceutical company Eli Lilly and Company (Lilly) has agreed to acquire ARMO Biosciences for $1.6bn.

Eli Lilly will buy each share of ARMO Biosciences for $50 in cash, as per the terms of the agreement.

The acquisition will help Eli Lilly to further improve its clinical portfolio adding ARMO Biosciences’ lead immuno-oncology asset pegilodecakin to its portfolio.

Eli Lilly has appointed Credit Suisse (USA) as financial adviser, and Wachtell, Lipton, Rosen & Katz as legal adviser for the transaction.

ARMO has appointed Centerview Partners as financial adviser.

Jefferies has been appointed as financial adviser, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian as legal adviser to ARMO.